Monthly Archives: June 2018

BAD NEWS: NY Court of Appeals reinstates flu vaccine mandates for pre schoolers

NY COURT of APPEALS REINSTATES NYC FLU MANDATES FOR NYC PRE-SCHOOL CHILDREN
     Earlier today the New York State Court of Appeals, New York’s highest court, released an unanimous decision supporting a New York City Board of Health regulation from 2013 requiring annual flu shots for children in pre-schools and daycare regulated by the City, overturning a lower court ruling, and a 5-0 Appellate division decision, rejecting the City’s claim that it had the authority to impose its own vaccine mandates. No further appeal is possible.
     The City’s regulation applies to children age 6 to 59 months, and only those programs under the supervision of the City of New York. Many daycare and pre-school programs are under the supervision of the New York State. Children at state supervised programs are not bound by the regulation. The Court recognized in the decision that religious and medical exemptions apply to the flu shot requirement.
     The decision appears to open the door to local governments across New York State to mandate vaccines in addition to those required by state law. New York City now joins Connecticut and New Jersey as the only places in the United States, and the developed democracies, that require flu shots.

READ MORE…

NY State Court of Appeals Adjudication document court of appeals – flu shot mandate – 64opn18-Decision

Neuropsychiatric Disorders Following Vaccination of Children & Adolescents:

Temporal association of certain neuropsychiatric Disorders
Following Vaccination of children and adolescents:

Department of Public Health Sciences, Pennsylvania State UniversityThe team looked for cases of OCD (obsessive-compulsive disorder), anxiety disorders, anorexia nervosa (AN), attention deficit hyperactivity disorder (ADHD), bipolar disorder, chronic tic disorder and major depressive disorder. What they found was shocking: Vaccinated children were more likely to experience any one of these issues. though the strongest correlation was between vaccination and the onset of anorexia nervosa.

The team looked at five years’ worth of private health insurance data for children between the ages of six and 15. They found that “young people vaccinated in the previous three to 12 months were significantly more likely to be diagnosed with certain neuropsychiatric disorders than their non-vaccinated counterparts.” READ More…

Study PDF download below

Vaccination:Psychiatricdisorders

Toddlers on psychiatric drugs

All Psychiatric       0-5 Years               622,723
Drugs

Breakdown:
0-1 Years                125,361
2-3 Years                202,319
4-5 Years                306,079

6-12 Years             3,259,955
13-17 Years           3,419,633

Grand Total           0-17 Years               7,213,599 kids on psychiatric drugs


ADHD Drugs          0-5 Years                80,235

Breakdown:
0-1 Years                328
2-3 Years                1,919
4-5 Years                77,396

6-12 Years             2,119,343
13-17 Years           1,524,381

Grand Total           0-17 Years               3,655,472 kids on ADHD Drugs


Antidepressants  0-5 Years                 38,534

Breakdown:
0-1 Years               6,687
2-3 Years               10,957
4-5 Years               21,299

6-12 Years            574,090
13-17 Years          1,503,185

Grand Total          0-17 Years               2,100,315 kids on antidepressants


Antipsychotics     0-5 Years                 85,143

Breakdown:
0-1 Years                3,913
2-3 Years                27,001
4-5 Years                53,750

6-12 Years             467,500
13-17 Years           646,215

Grand Total           0-17 Years               1,194,805 kids on antipsychotics


Anti-anxiety           0-5 Years                   389,558

Breakdown:
0-1 Years                  102,960
2-3 Years                  148,894
4-5 Years                  143,692

6-12 Years               484,612
3-17 Years               577,259

Grand Total             0-17 Years               1,445,509 kids on anti-anxiety drugs

VLA COMMENT:  This was published in 2013.  Prescription drug use as increased since then.

Why are toddlers, children and adolescents getting prescribed these heavy drugs?

Because they are getting 49 vaccine doses with vaccine excipents that cannot be metabolized, causing poisoning and damage to their neurology, immune system, depression, suicide as young as seven years old…hanging from a belt in his closet or dangling from the canopy.  See: www.SSRISTORIES.NET 

Learn more about the mechanics: PHARMACOGENOMICS/SUICIDES, HOMICIDES AND SCHOOL VIOLENCE. 

Pediatric study

JAMA STUDY: Depression: An Adverse Effect of Prescription Medication

IMPORTANCE: Prescription medications are increasingly used among adults in the United
States and many have a potential for causing depression.
OBJECTIVES: To characterize use of prescription medications with depression as a potential
adverse effect and to assess associations between their use and concurrent depression.

Prescription medications are widely and increasingly
used in the United States, with approximately 15% of
adults estimated to have been using 5 or more concurrent
prescription medications in 2011 and 2012.1 Alongside evidence
that adverse drug events from prescription medications
are often implicated in emergency department visits and
hospitalizations,2 there is gaining recognition thatmany commonlyused
prescriptionmedications, includinghormonalcontraceptives
and β-blockers, are associated with an increased
risk of depression.

CONCLUSION: In this cross-sectional survey study, use of prescription
medications that have depression as a potential adverse effect was common. Use of multiple
medications was associated with greater likelihood of concurrent depression.

Read study:  JAMA_drugs_linked_to_depression(1)

The real cause is found in PHARMACOGENOMICS and drug metabolism

Must read:  Pharmacogentics, Suicide, Homicide and school violence

List of sucides and homicides on psychiatric drugs: www.SSRIStories.net

Pediatric Study: Pharmacogenomics – Adverse Reaction in Children

Drug-Metabolizing Enzyme Genotypes
and Aggressive Behavior Treatment Response
in Hospitalized Pediatric Psychiatric Patients

TracyGlauser Pharma study

Objective: The aim of this study was to examine the association between the CYP2D6 and CYP2C19 genotypepredicted combined phenotypes and short-term measures of psychotropic efficacy and toxicity.
Methods: A rater-blinded, retrospective genotype association design examined a cohort of hospitalized pediatric psychiatric patients genotyped for CYP2D6 and CYP2C19 as part of clinical care. These combined genotypes were used to predict a combined phenotype. The primary efficacy outcome measure was the behavior intervention score (BIS), a function of the number of recorded timeouts=seclusions, therapeutic holds, and physical restraints.

Patient response to commonly used psychotropic medications demonstrates significant variability; only 30–75% of patients experience efficacy, whereas 65–75% encounter ad-
verse events (Kirchheiner et al. 2004; Emslie et al. 2006; Kratochvil et al. 2006; Hetrick et al. 2007). Many psychotropic medications are metabolized by cytochrome P450 (CYP) en-
zymes coded for by the polymorphic genes CYP2D6(þ124030) and CYP2C19 (*124020).
The relationships between the distinct CYP2D6 or CYP2C19 genotypes and the pharmacokinetics of psychotropic medications are the basis for genotype-based dosing recommendations for some medications (Kirchheiner et al. 2001).Despite the prevalence of the problem, the contribution of drug-metabolizing enzyme genotypes to the variability in aggressive behavior treatment response in hospitalized pediatric psychiatric patients is unknown. The purpose of this study was to examine the association between CYP2D6 and CYP2C19 genotype-predicted metabolizing phenotypes and short-term measures of drug efficacy (incidence of behavioral interventions for aggressive behavior) and toxicity (adverse drug reaction)

Drug tolerability was defined as the total number of recorded adverse drug reactions.

 

Conclusion
Identifying factors underlying the variability in drug efficacy
or tolerability is a key component for optimizing the patient’s
response to therapy. This is the first study to demonstrate that,
for children hospitalized for psychiatric conditions,
CYP2D6 and CYP2C19 genetic variation contributes to psychotropic…
Consideration of a patient’s genotype at the onset of a psychiatric hospitalization could play a significant role in personalizing and improving subsequent therapy.
Prospective longitudinal studies are necessary to better inform
how to optimally incorporate this genetic information into the
medical management of patients with aggression. In summary,
this study indicates that CYP2D6 and CYP2C19genotypes are
 important in the clinical care of children with psychiatric diagnoses requiring medications that are metabolized throughthese two enzyme pathways.

Find out about pharmacogenomic: Cytochrome P450, homicide, suicide and school violence

Pharmacogentics, Suicide, Homicide and school violence

INFANT VACCINES/Cytochrome P450 and failure of infants to metabolize vaccine excipients  READ

Accounts of thousand of Suicides and Homicides: www.SSRIStories.net

Goldman: Chicken Pox/ SHINGLES? (story of CDC obstruction and denial)

Review of the United States universal varicella vaccination program: Herpes
zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data

In a cooperative agreement starting January 1995, prior to the FDA’s licensure of the varicella vaccine on March 17, the Centers for Disease Control and Prevention (CDC) funded the Los Angeles Department of Health Services’ Antelope Valley Varicella Active Surveillance Project (AV-VASP). Since only varicella case reports were gathered, baseline incidence data for herpes zoster (HZ) or shingles was lacking.

Goldman VaricellaAntelopeValley

VLA COMMENT:  The near eradication of the early childhood Chicken Pox has resulted in people who have had natural wild chickenpox as children are not getting their”subtle” exongenous boosters from the subsequent generation of our children or our grandchildren who unfortunately  are prevented from getting  wild chicken pox, They  are getting vaccinated with a different strain that can’t boost us. So, in essence, the CDC has simply brought another chicken pox strain into existence.  Now we have two. However, the wild typeis not prevelant enough to give us the necessary booster so we don’t get shingles.

Dr. Gary Goldman:  The reason why we are getting SHINGLES

The only reason that “children who get the chickenpox vaccine APPEAR to have a much lower risk of shingles” is that the live vaccine has provided these children with a recent boost to their immunity. However, the vaccine-strain of varicella zoster virus (VZV)–also known as the Oka strain–is genetically different from the wild-type U.S. strain. When a vaccinated child is exposed to an adult with shingles or a child with wild-type varicella, if the strains are sufficiently heterologous, the vaccinated child will break out in chickenpox. It is also possible for the weakened vaccine-strain to revert to a more virulent strain that manifests wild-type pathology. This means when children are exposed to the wild-type strain, even though they may not have a breakthrough infection with chickenpox, they now harbor two heterologous (genetically different) strains of VZV–both of which are at a later time subject to reactivation as shingles. Thus, as they age, they will be even more likely to reactivate with shingles (unless periodically administered booster vaccine doses for life in order to maintain the immunity)–especially if they do not receive exogenous (outside) boosts to their cell-mediated immunity which, in the pre-vaccine era, came from expostures to other children infected with wild-type varicella which provided the adult with a subclinical boost that helped to suppress or postpone reactivattion of shingles.

I would also like to clear up the point that shingles has always been increasing–even prior to the licensing of the varicella vaccine. This statement is true; however, the increases were on the order of 2 to 4% per year (which were likely due to an aging population, or greater access to healthcare). Once a community had widespread distribution of varicella vaccine, increases in herpes zoster were on the order of 20% per year. For example, this source [Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005; 5:68.
32. Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev 2010; 23(1):202–217] found a 90% increase in shingles over 5 years (1999-2003).

Pharmacogenetics/Cytochrome P450/Suicides & Homicides/school violence

Brandon Turbervile comprehensive article:  Psychiatric Drugs, School Violence, and the Big Pharma Cover-up

Excerpts:

the CYP450 enzymes are the primary catalysts for detoxification reactions that render water-insoluble molecules sufficiently water soluble to be excreted in the urine. . . . Drugs, hormones, toxins, carcinogens, mutagens, environmental pollutants, and other xenobiotics are metabolized by CYP450 enzymes.

Of the CYP450 enzyme family, there are other more specific enzymes such as CYP2C9, CYP2C19, and CYP2D6, etc. These three enzymes specifically are responsible for approximately 40% of all CYP450-mediated drug metabolism. The CYP2D6 enzyme itself is responsible for the bulk of drug metabolism at around 20% to 30% of drug metabolism in the CYP450 family.

In relation to the CYP2D6 enzyme, there are four classifications – Extensive Metabolizers (EM), Poor Metabolizers (PM), Intermediate Metabolizers (IM), and Ultrarapid Metabolizers (UM).
EM (Extensive Metabolizers) are considered the “normal genotype,” “which is free of inactivating polymorphisms, deletions, or duplications.”  PM (Poor Metabolizers) are individuals who have “deficient” enzyme function in terms of CYP450 metabolic processes and, subsequently, have difficulty clearing certain medications. IM (Intermediate Metabolizers) are those who have some functioning CYP450 enzymes but are subject to loss of the function of these enzymes after the “second hit” of medication, thus turning them into PM. UM (Ultrarapid Metabolizers) are those who metabolize the drug so rapidly that it clears so quickly that there is little or none of the desired effect.  In medications that required metabolism to activate, however, UM individuals the metabolite may be produced too quickly, resulting in toxicity and the realization of side effects.
While there are potentially adverse health effects with any one of the four classifications, the focus of this article is on those who are generally PM (Poor Metabolizers). This is because these individuals have a higher chance of experiencing adverse health effects of pharmaceuticals than those with “normal” functioning EMCYP2D6 enzymes.
Synopsis:  Infants do not have a mature liver or liver enzyme function such as Cytochrome P450 and its various metabolites until the age of three years old. Hence upwards of 36 vaccine doses by 18 months old containing the above excipients are poisoning the world’s emerging humanity.
SPECIAL PHARMACOKINETICS AND PHARMACODYNAMIC CONSIDERATION IN CHILDREN

Mayo Clinic Conference on Pharmackinetics Sept. 2018